
Italy · Research startup
Altheia Science is a biotechnology startup based in Milan, Italy, founded in 2017.
Funding reportedLast round: Series A
Follow Altheia Science and see its new rounds in your feed.Start following
Altheia Science is a biotechnology startup based in Milan, Italy, founded in 2017.
The company focuses on developing curative cell and gene therapies for patients with autoimmune diseases and cancer. Its innovative approach involves modulating PD-L1 expression to restore immune tolerance and eliminate autoreactive T lymphocytes. This strategy aims to significantly impact conditions like Type 1 diabetes and multiple sclerosis. The company is led by founders Prof. Alessandra Biffi and Prof. Paolo Fiorina, with Paolo Rizzardi serving as CEO. Altheia Science operates primarily in the biotechnology research sector and is a private company with a small team of about 6 to 7 employees. Its therapeutic pipeline includes PD-L1 modulating stem cell therapy for autoimmune diseases and CAR-T immunotherapy targeting specific cancers. Altheia Science is committed to providing durable benefits to patients through its advanced therapeutic strategies.
Funding, as reported
What they build
Known for
health careoncologyautoimmunityliquid tumor therapypreclinical modelsliquid tumorsimmune regulationbiotechnology researchcar-t cell engineeringcancer cell targetinghealthcareneurodegenerative disease therapyautoimmune disease reversalmedical researchautoimmune diabetesliquid tumor targeting
Built with from their website
Microsoft 365SiteGroundSiteGround DNSGoogle Cloud Hosting
Add your raise, your deck and your story, and put Altheia Science in front of investors. Or tell us what we have wrong.